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This preliminary investigation aimed to assess beta (β) oscillation, a marker of the
brain GABAergic signaling, as a potential objective pain marker, hence contributing
at the same time to the mechanistic approach of pain management. This case–
control observational study measured β electroencephalographic (EEG) oscillation in
12 right-handed adult male with chronic neuropathic pain and 10 matched controls
(∼55 years). Participants were submitted to clinical evaluation (pain visual analog scale,
Hospital Anxiety, and Depression scale) and a 24-min high-density EEG recording
(BIOSEMI). Data were analyzed using the EEGlab toolbox (MATLAB), SPSS, and R.
The global power spectrum computed within the low (Lβ, 13–20 Hz) and the high
(Hβ, 20–30 Hz) β frequency sub-bands was significantly lower in patients than in
controls, and accordingly, Lβ was negatively correlated to the pain visual analog scale
(R = −0.931, p = 0.007), whereas Hβ correlation was at the edge of significance
(R = −0.805; p = 0.053). Patients’ anxiety was correlated to pain intensity (R = 0.755;
p = 0.003). Normalization of the low and high β global power spectrum (GPS)
to the GPS of the full frequency range, while confirming the significant Lβ power
decrease in chronic neuropathic pain patients, vanished the significance of the Hβ
decrease, as well as the correlation between Lβ power and pain intensity. Our results
suggest that the GABAergic Lβ EEG oscillation is affected by chronic neuropathic pain.
Confirming the Lβ GPS decrease and the correlation with pain intensity in larger studies
would open new opportunities for the clinical application of gamma-aminobutyric
acid-modifying therapies.
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INTRODUCTION
Pain is a major public health challenge, and a large number of
available analgesic drugs do not prevent from high treatment
failure rate (Mantha et al., 1993). Despite the great variety of
pain etiologies, all pain types are treated using similar drugs,
irrespective of their underlying mechanisms (Vargas-Schaffer,
2010), which could explain why successful analgesia is hard to
reach. A mechanism-based classification of pain could probably
help improving treatment efficiency. Several neurotransmitters
are involved in nociception (Schaible, 2007; Ossipov et al.,
2010), including gamma-aminobutyric acid (GABA), the major
brain inhibitory neurotransmitter, which plays a critical role in
different pain processing steps (Enna and McCarson, 2006; Barr
et al., 2013). Thus, the GABAergic signaling could be a suitable
candidate for a mechanism-based approach to characterize
and manage pain.
Pain can be evaluated by means of several clinical tools,
among which the Visual Analog Scale (VAS), the Numerical
Rating Scale (Haefeli and Elfering, 2006; Hawker et al., 2011),
and the Brief Pain Inventory (BPI), the latter taking also
into account the complexity and the impact of pain on
multiple domains of life, such as sleep and mood (Cleeland
and Ryan, 1994; Tan et al., 2004; Shi et al., 2017). These
scales are all based on the patient’s subjective pain perception,
which is influenced by many factors, such as the cognitive
state, mood, etc. On the other hand, many brain areas
contributing to pain regulation (within the pain matrix) are
also involved in several other functions, such as cognition,
emotion, motivation, or other sensory modalities (Ossipov et al.,
2010). For all these reasons, the pain matrix structure and
function (and thereby pain perception) can be influenced by
all the factors mentioned earlier (Bushnell et al., 2013). This
complex interplay between factors interfering with both pain
regulation and its subjective perception makes it difficult to
find a comprehensive assessment tool. Hence, the need for a
complementary evaluation, based on more objective criteria, e.g.,
biomarkers related to physiological pain mechanisms, that could
contribute to characterize further and hopefully better manage
pain (Archibald et al., 2018).
Successful analgesia is achieved when pain intensity (evaluated
by the VAS) is <3 (Mantha et al., 1993). This pain level could
be considered as a cutoff value defining in a very simple way
what a “significant” pain is, even if other classifications of pain
severity exist (Mantha et al., 1993; Collins et al., 1997). The
Abbreviations: α, Alpha; BPI, Brief pain inventory; BPImood, Brief pain
inventory score related to the mood (question n◦9b); CNP, Chronic neuropathic
pain; δ, Delta; dB, Decibel; DN4, Douleurs neuropathique 4 questions;
EEG, Electroencephalogram/Electroencephalography/Electroencephalographic; γ,
Gamma; GABA, Gamma-aminobutyric acid; GPS, Global power spectrum; GPSq,
Global power spectrum of a scalp quadrant; GPSqmax, the highest power of the
Global power spectrum in a scalp quadrant; GPSqmin, the lowest power of the
global power spectrum in a scalp quadrant; HAD, Hospital anxiety and depression;
HADanx, Hospital anxiety and depression subscore for anxiety; Hβ, High beta;
Hz, Hertz; Lβ, Low beta; θ, Theta; TMS, Transcranial magnetic stimulation;
VAS, Visual analog scale; VASd, Visual analog scale recorded the same day as
the electroencephalogram; VAS2w , Visual analog scale of the last 2 weeks before
electroencephalogram.
International Association for Studies of Pain defines chronic
pain as lasting for more than 3 months (Fine, 2011; Treede
et al., 2015). However, the concept of chronic pain refers to the
prolonged duration of pain because substantial and long-lasting
changes are thought to occur within the pain matrix in this
context (Schaible, 2007; Baliki et al., 2012; Baliki et al., 2014).
Animal experimental data show that, in chronic pain situations,
virtually the whole set of neurotransmitters (including GABA and
glutamate) modify their functioning in pain regulating regions.
This ultimately leads to an imbalance between excitation and
inhibition in favor of excitation (Ossipov et al., 2010; Pinheiro
et al., 2016). Therefore, one could expect the brain inhibitory
input (mainly mediated by the GABAergic signaling) to lower
under these conditions. Some studies show indeed a decrease
in cortical inhibition correlated to pain intensity (Barr et al.,
2013; Henderson et al., 2013; Parker et al., 2016), whereas others
show the opposite (i.e., an increase of inhibition) (Sarnthein
et al., 2006; Lim et al., 2016). Most of these preliminary studies
were conducted in patients suffering from the pain of different
origins, using varied electrophysiological and brain imaging
techniques and methods, and data analysis was most of the time
not standardized.
Brain GABAergic activity can be measured via several
techniques, including transcranial magnetic stimulation (Premoli
et al., 2014), and electroencephalography (EEG), a noninvasive,
cheap, and readily accessible tool to assess brain electrical
activity (Barr et al., 2013). The beta (β, 13–30 Hz) and gamma
(γ, 30–100 Hz) EEG oscillations represent an index of the
brain’s GABAergic activity, as they are mainly produced by
inhibitory interneurons (Gaetz et al., 2011; Christian et al.,
2015; Baumgarten et al., 2016). Electroencephalographic studies
of pain-related GABAergic signaling focus mostly on the γ
frequency domain, although γ waves are generated deep in the
brain and are therefore not easy to record with scalp EEG
(Rutkove, 2007). On the contrary, data concerning pain-related
β EEG activity are scarce (Barr et al., 2013; Bushnell et al., 2013;
Pinheiro et al., 2016), whereas β activity, related to the amount of
GABA in the somatosensory cortex (Baumgarten et al., 2016), is
more reliably measured by scalp EEG.
Thus, brain GABAergic activity can be reliably measured by
EEG β oscillations. In a mechanistic approach of pain assessment,
β oscillations could represent an index of the GABAergic
component of pain. This pilot case–control study aimed,
therefore, at recording β EEG oscillations in patients suffering
from chronic neuropathic pain (CNP), with the hypothesis that
β waves would decrease and be negatively correlated with pain
intensity, in accordance with most convincing data (Harris and
Clauw, 2012; Barr et al., 2013; Parker et al., 2016).
MATERIALS AND METHODS
Study Design
This case–control cross-sectional, observational study involved
patients suffering from CNP and sex (all males)-matched healthy
controls of similar age (±5 years). Participants were recruited and
investigated between September 2015 and January 2018.
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Participants
Patients (all right-handed) suffered from CNP due to a peripheral
nerve lesion in the lower limbs lasting for ≥6 months. The
diagnosis of peripheral neuropathy was made by a specialist
(neurologist, pain specialist, or an orthopedist specialized in
spine surgery) and supported by a “Douleur Neuropathique 4
questions” (DN4) (Bouhassira et al., 2005; Bennett et al., 2007)
score of ≥4. Exclusion criteria were the presence of any central
nervous system lesion or disease (including epilepsy, parasomnia,
and cognitive impairment), the coexistence of other types of
pain, and analgesic surgical interventions within less than 6
months before inclusion. Sex- and overall age-matched controls
[independent t-test: t(16.955) = 0.358; p = 0.738] fulfilled the
same inclusion (except for the presence of pain) and exclusion
criteria as patients.
The study fulfilled the requirements of the Declaration of
Helsinki and was approved by the Ethics Committee of Vaud
under the reference 331/15. Each participant signed informed
consent before any investigation.
Data Collection
Interview, Clinical Examination, and Clinical Scores
In total, 16 CNP patients and 14 healthy controls were screened.
Among them, two controls were finally excluded because they
happened to have exclusion criteria upon a second check. All
recruited participants underwent individual, in-person interview
following a standardized questionnaire including personal and
medical data and information on their sleep behavior. In
addition, sleep-related [Insomnia Severity Index (Omachi, 2011)]
and mood-related [Hospital Anxiety and Depression (HAD)
(Zigmond and Snaith, 1983)] scales were compiled. Three
additional scales related to pain were included in patients’
assessment: the DN4, to confirm the neuropathic pattern of pain
(Bouhassira et al., 2005; Bennett et al., 2007), the VAS, to quantify
pain intensity (Collins et al., 1997), and the BPI, French version
(Poundja et al., 2007), to further characterize pain and evaluate
its impact on patients’ life (Kerns et al., 1985). For the purpose of
the analysis included in this paper, only data related to pain and
mood were considered.
Clinical examination was performed by medical doctors (JNC
and JMA) or one trained medical student (MT) to confirm lower-
limb localization of pain and absence of exclusion criteria.
Electrophysiological Recordings
All EEG recordings took place in the morning to exclude
bias due to nychthemeral variations of pain (Strian et al.,
1989). During EEG recordings, participants sat alone in a
quiet room shielded in a Faraday cage and were requested
to minimize eye blinks or any other body movements. The
EEG recording protocol consisted of a 24-min resting-state
paradigm (i.e., without any task involvement), mostly with eyes
closed (Figure 1A), a condition considered to reflect a basal
arousal state and accompanied by an increased alpha frequency
amplitude (Barry et al., 2007). The alpha (α) global power
spectrum (GPS) averaged over all patients for epochs recorded
in eye-closed (Figure 1B) vs. in eye-open (Figure 1C) conditions
appeared to be different. The visual difference observed between
the two topoplots was indeed statistically confirmed, showing
∼100 times higher power with eyes closed (p = 0.002). Similar
results were observed in controls (more than 10 times higher
GPS in the eye-closed condition; not shown in the figure):
2.07 (3.81) dB for the eyes-closed condition and −0.13 (3.42)
dB for the eyes-open condition [t(9) = −4.186, p = 0.002].
Thus, lower α amplitudes in the eye-open condition confirm
significant changes occurring in EEG signals, which could have
introduced a bias in our analysis of other frequency bands if
not taken into account. For this reason, only data recorded in
the eye-closed condition were considered when performing all
remaining analyses.
The EEG data were continuously recorded at 1,024 Hz
using a high-density (64 electrodes) EEG (BIOSEMI ActiveTwo)





Automated data preprocessing was performed using a
customized MATLAB script based on the EEGLab Toolbox
(Delorme and Makeig, 2004) and on the preprocessing pipeline
developed by Bigdely-Shamlo et al. (2015) First, raw EEG
data were re-referenced to the Cz electrode, down-sampled
to 512 Hz, and band-pass filtered between 1 and 60 Hz for
artifact removal preparation (Winkler et al., 2015). Automated
artifact rejection algorithms (EEGLab plugins) were applied
to remove sinusoidal noise stemming from alternating current
power line fluctuations [CleanLine (Mullen, 2012)] or high
amplitude eyes movements, muscle artifacts, and electrode
drifts [Artifact Subspace Reconstruction (Chang et al., 2018)].
Channel interpolation algorithms were used to detect any flawed
channels (limited to a maximum of seven rejected electrodes).
Preprocessed EEG data were then segmented in 2-s epochs,
and two additional artifact detection algorithms were applied
to ensure adequate cleaning of epoched data. Finally, re-
referencing to average reference was mandatory before all
spectral analyses.
It was important to analyze only data recorded in wakefulness
because sleep stages were expected to interfere with fast EEG
oscillations, including beta waves (Barry et al., 2007). Data
analysis was based on a windowed Fourier transform. This was
performed with MATLAB and the EEGLab toolbox for MATLAB.
To automatically select data recorded in wakefulness state, a
data-driven analysis was developed following empirical evidence
(Diaz et al., 2016). This method computes the ratio between the
α (8–12 Hz) and the Theta (θ, 5–7 Hz) GPS. For this purpose,
a 4-s windowed fast Fourier transform was performed (on 4-s
windows obtained by regrouping adjacent 2-s epochs). Only 4-
s windows with α/θ ratio ≥1 were considered to be recorded
in wakefulness and selected for further analyses. Selected epochs
were finally submitted to a 2-s windowed Fourier transformation
for frequency analysis between 2 and 48 Hz to minimize
electronic devices’ noise and because all frequencies of interest
were below 48 Hz.
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FIGURE 1 | Resting-state EEG recording protocol (A). This 24-min experiment started with a 2-min period, during which the participant opened his eyes (yellow
color), and for the rest of the experiment, the eyes had to remain closed (green color). Four acoustic cues (“beeps,” vertical arrows) were presented to the participant
during the experimental session to warn him about the ongoing experimental step, i.e., to switch to the eye-closed condition or to keep him awake. Each participant
was instructed concerning the meaning of each acoustic cue before the beginning of the experiment. First and last beeps (t0 and t3, respectively) determined the
beginning and the end of the experimental session, respectively. Second beep (t1) occurred 2 min after t0 and instructed the participant to close his eyes, whereas
the third beep (t2) occurred in the middle of the experiment and was implemented to maintain the participants awake as they tend to fall asleep. Alpha GPS-derived
topoplots in all chronic neuropathic pain patients during eye-closed (B) and eye-open (C) experimental steps. The color bar at the right side of the figures represents
ascending alpha power values from the lowest at the bottom [blue, 50 10*log10 (µV/Hz)] through the highest at the top [red, 63 10*log10(µV/Hz)]. As expected, two
alpha peaks were observed in posterior regions on the left and the right side, respectively, during the eyes-closed condition (B, left topoplot). On the contrary, these
prominent peaks disappeared when the eyes were open (C, right topoplot). GPS significantly differed between eye-closed [−0.02 (4.21) dB] and eye-open [−2.17
(4.15) dB] conditions [t(11) = −4.072, p = 0.002].
In the present paper, only data concerning the β (13–
30 Hz) and the delta (δ, 2–4 Hz) frequency range are presented.
The δ frequency was selected as a negative control, owing
to the absence of clear links between δ oscillations and
chronic pain in the literature (Pinheiro et al., 2016). The
GPS for a given frequency was computed by averaging the
respective frequency power data across all epochs recorded
over all electrodes in a particular participant. A logarithmic
transformation was used to obtain near-normally distributed
data (Gasser et al., 1982). Unless otherwise specified, all data
are presented in this log-transformed version. Data were then
converted to decibel to remove any artefactual constant activity
in the signal (represented in the results section as 10∗log10)
(Delorme and Makeig, 2004).
Initial analyses evidenced that the β frequency domain was
characterized by two prominent “peaks” (maxima) of power in
most subjects, located approximately at 16 and 25 Hz, which
corresponded to the centers, respectively, of the Lβ (13–20 Hz)
and the Hβ (20–30 Hz) frequency sub-bands (von Rotz et al.,
2017). Therefore, all subsequent spectral analyses were performed
separately in the two defined β sub-bands.
Data Normalization
Normalization of computed Lβ and Hβ GPS to the GPS
over the total analyzed frequency range (1–60 Hz; GPStotal)
was performed as follows: first, the logarithmic transformation
used in the analysis of the non-normalized data to obtain
near-normally distributed data was inverted, after that, the
respective ratio between Lβ (GPSlβ) and Hβ GPS (GPShβ)
and the GPStotal were computed, and finally, the logarithmic
transformation of the ratio was computed back to obtain
the normalized GPS (GPSnormalized). The following formula
summarizes the normalization procedure for the Lβ GPS: Lβ
GPSnormalized = 10∗log10 [10∗∗(GPSlB/10)/10∗∗(GPStotal/10)].
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Beta Power Maxima and Minima Localization
To localize the power maxima on the scalp (i.e., in the sensor
space), the horizontal head section was divided into four
quadrants in a way that avoided misleading or ambiguous
interpretation (adapted from Grabner and De Smedt, 2012).
After averaging β power over all electrodes in each quadrant
(following the same procedure as for the GPS; see spectral
analysis earlier), the computed GPS was named GPSq. The
quadrant with the highest power was considered to be the
localization of the maximal β GPSq (GPSqmax). The procedure
to compute the minimal GPS (GPSqmin) was exactly the same as
for the GPSqmax, except that the minimum power was depicted
instead of the maximum.
Statistical Analyses
Statistical analyses were performed using the SPSS 24.0
software (IBM SPSS Statistics). All log-transformed EEG data
(GPS) were successfully tested for normality (Kolmogorov–
Smirnov test and visual inspection of data distribution).
Unless otherwise specified, data are expressed as mean (SD).
Differences among δ, Lβ, and Hβ frequency bands within
groups were assessed using a multivariate analysis of variance.
Group differences were evaluated using post-hoc Student’s
t-test, and the significance threshold (set at p < 0.05, 95%
confidence interval) was corrected for multiple comparisons
with the Bonferroni method (αc = 0.017). Correlations




All participants underwent a formal interview and participated in
the EEG assessment. However, only 12 patients and 10 controls
were retained for the final analysis [mean age 54.4 (8.0) and 56.3
(15.6) years, respectively], as four patients had a DN4 score <4,
whereas two controls suffered from low-intensity pain at the time
of EEG assessment. Unless otherwise specified, analyses were
performed in all CNP patients (n = 12) and/or in all controls
(n = 10) as appropriate.
Patients had a DN4 score distributed between 4 and 8 [5.7
(1.3)]. Table 1 gives an overview of pain-causing peripheral
neuropathy types and etiologies. The great majority of patients
suffered from painful radiculopathy related to spine arthrosis,
whereas the few remaining cases had polyneuropathy due to
diabetes or suspect of paraneoplastic origin. Most patients also
reported other sensory symptoms such as tingling, prickling,
hypoesthesia, etc. Less than half of them benefited from
nonsurgical treatments alone or in combination (nonsteroidal
anti-inflammatory drugs, antidepressants, opiates, or even
alternative treatment methods). Table 2 shows additional
individual information on pain intensity recorded via the VAS.
The level of pain on the day of the EEG recording (VASd)
was in general slightly lower than pain intensity perceived on
average during the last 2 weeks [VAS2w; respectively, 3.2 (2.1)
and 4.2 (1.6)/10; p = 0.05 with a paired t-test]. Answers to
TABLE 1 | Patients’ information concerning pain etiologies, associated sensory
symptoms, and analgesic treatment.





Lumbar/sacral neuralgia Spine arthrosis with root compression 9
Subtotal 9














Physical and alternative 3
NSAID, Nonsteroidal anti-inflammatory drugs.
TABLE 2 | Pain intensity scores (significant levels in bold) and predominating pain
side in CNP patients.
Patients no. VASd VAS2w Pain side
1 1 3 R
2 2.5 3 R
3 0.5 5 L
4 3 5 R
5 1.5 2 L
9 8 8 R
11 2.5 4 L
12 2.5 3 L
13 3 6 L
14 3.5 4 R
15 4 3 L
16 6.5 5 R
Mean 3.2 2.1 4.2 1.6 50%R; 50%L
CNP, chronic neuropathic pain; VASd, Visual Analog Scale assessed the day of the
EEG recording; VAS2w, VAS referring to the 2 weeks before the EEG recording day;
L, left; R, right.
question no. 6 of the BPI questionnaire [French version (Poundja
et al., 2007)] corresponded exactly to the VASd (Tittle et al.,
2003) (R = 0.992, p < 0.001), whereas the level of pain in
general (question no. 5 of the BPI questionnaire) was similar
to the VAS2w (R = 0.982, p < 0.001), further confirming
that the VAS2w represented the intensity of pain perceived by
patients in general.
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Spectral Analysis
In all 22 participants, power spectral densities were computed
following windowed fast Fourier transforms after appropriate
preprocessing (see section “Materials and Methods”). The output
of this analysis is shown in one illustrative patient and one
control, respectively, in Figures 2A,B. The frequencies of interest
are highlighted in gray (δ), red (Lβ), and green (Hβ) colors. In
addition to the prominent α peak (see section “Materials and
Methods”), the two peaks defining the Lβ and the Hβ frequency
sub-bands (von Rotz et al., 2017) (see also the insets of these two
figures representing the GPS over the whole frequency spectrum)
are visible around 16 and 25 Hz. Lower power in the Lβ and the
Hβ domains in patients compared with controls can already be
suspected at this stage (inset graph scales are similar).
Global Power Spectra in the Lβ and Hβ Sub-Bands,
and δ Band
As shown in Figure 2C, both Lβ and Hβ GPS were significantly
lower in patients [−4.7 (2.0) and −7.7 (1.9) dB, respectively] than
in controls [−1.4 (2.9) and −5.4 (1.2) dB, respectively] (p = 0.004
for both EEG markers). There was a significant effect of frequency
[F(2, 40) = 225, 93, p < 0.001] and of group [F(1, 20) = 12.37,
p = 0.002] but no interaction [F(2, 40) = 2.41, p = 0.102]. On the
contrary, there was no statistical difference in the δ GPS between
patients [2.0 (1.7) dB] and healthy participants [3.4 (1.7) dB;
p = 0.069] (Figure 2C). The significance threshold (α = 0.05) was
corrected to αc 0.017 with the Bonferroni method for multiple
(n = 3) comparisons.
After normalizing Lβ and Hβ GPS to the GPS over the full
range of frequencies band-filtered for data analysis (see section
“Materials and Methods” for details), CNP patients still had
significantly lower Lβ GPS compared with controls [respectively,
3.7 (1.4) and 5.7 (2.8) dB, p = 0.041], whereas the decrease noticed
in the Hβ frequency range lost significance [0.8 (1.4) and 1.6 (1.1)
dB, p = 0.123] (Figure 2D).
Power Maxima and Minima Localization
As an attempt to localize the maximal and the minimal β power
in the sensor-space, we computed β GPS for the four defined
quadrants (GPSq; see section “Materials and Methods” for the
detailed procedure) and considered the quadrant holding the
maximal GPSq (GPSqmax) and the minimal GPSq (GPSqmin) as
the localization of, respectively, the β maximum and minimum.
In the Lβ range, most patients (regardless of their predominant
pain side) and controls displayed GPSqmax in the posterior,
left region (75 and 80%, respectively). The pattern of GPSqmax
localization was different in the Hβ range: 58.3% of patients
showed the maximal averaged power in the anterior, left
quadrant, whereas 70% of controls displayed their GPSqmax
within the right hemisphere (equally distributed in anterior
and posterior regions). The GPSqmin was variably distributed
in controls (Lβ frequency: 70% in the anterior left, 17% in the
posterior right; Hβ frequency: 40% in the anterior left and 50%
in the posterior right), and in CNP patients [in the Lβ range:
50% in the anterior left quadrant, 33% in the anterior right, and
17% in the posterior right; in the Hβ range: 50% in the posterior
right, the rest being equally observed (17%) in the three other
quadrants], no relationship being observed with the predominant
pain side. Here also, no remarkable difference was observed
between patients and controls.
Correlations Between
Electroencephalographic Markers and
Pain Intensity in Patients
The GPS was clearly lower in patients than in controls, both in
the Lβ and in the Hβ frequency ranges. Thus, we expected a
negative correlation between the VAS and the GPS for both EEG
markers. On the day of the EEG recording, patients had pain
levels at the limit of significance (VASd ∼3) (Mantha et al., 1993;
Jensen et al., 2003; see Table 2). When relating their VASd to
the GPS, no significant correlation was found, neither in the Lβ
range (R = −0.453; p = 0.139) nor in the Hβ range (R = −0.349;
p = 0.349). Interestingly, when we further discriminated between
patients with nonsignificant pain (VASd < 3) and those with
significant pain (VASd ≥ 3), no correlation was found in the
absence of significant pain (n = 6) (Lβ: R = −0.418; p = 0.409;
Hβ: R = 0.253; p = 0.629), whereas in patients with VASd ≥ 3
(n = 6), a strong correlation was now observed both in the Lβ
(R = –.931; p = 0.007), while only at the edge of significance
in the Hβ range (R = −0.805; p = 0.053). None of the two
GABAergic markers was correlated to the VAS2w (Lβ: R =−0.133;
p = 0.680; Hβ: R = −0.281; p = 0.376), even when splitting
between patients with VAS2w < 3 and VAS2w ≥ 3 (data not
shown). The GPS in the δ range did not correlate neither with the
VASd (R = −0.385; p = 0.216 for) nor with the VAS2w (R = 0.282;
p = 0.375), even when only considering patients with VAS ≥ 3
(data not shown).
Upon normalization, no correlation was anymore observed
between Lβ GPS and VASd (R = −0.061, p = 0.851), even when
solely evaluated in CNP patients with VASd ≥ 3 (R = −0.118,
p = 0.824). There was no correlation between Hβ GPS and VASd
(data not shown).
Relation Between Mood and Pain
Because mood interacts with pain (Klyne et al., 2018),
participants were administered the HAD questionnaire (see
section “Materials and Methods”) (Zigmond and Snaith, 1983;
Bjelland et al., 2002). Patients (n = 12) were moderately anxious
[HADanx sub-score; 8.9 (3.6)] but not controls [5.3 (2.8)]
[t(20) = 2.541, p = 0.019], and the depression sub-score was
normal in both groups [5.5 (4.3) and 2.2 (1.3), respectively].
Interestingly, the HADanx positively correlated with the VASd
in patients (R = 0.755; p = 0.003) most probably due to
the subgroup with VASd ≥ 3 (n = 6), which was the only
one displaying a significant, positive correlation (R = 0.895;
p = 0.016), contrary to the one with VASd < 3 (R = 0.375;
p = 0.464). No correlation was found between VAS2w (n = 12)
and HADanx (data not shown). Altogether, these observations
suggest that anxiety and pain intensity interacted daily but not
on average. It was also interesting to assess the impact of pain
on mood state. BPI question no. 9b (BPImood) is specifically
related to this issue. The BPImood score was highly correlated
to HADanx (R = 0.711, p = 0.01). Thus, pain-diseased patients
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FIGURE 2 | Power spectral densities averaged over all selected epochs in one chronic neuropathic pain patient (A) and in one control (B). In both graphs, power
spectral densities obtained in the eye-closed condition, after selection of epochs recorded in wakefulness and 2 s-windowed-Fourier transform between 2 and
48 Hz (see section “Materials and Methods”), were plotted against the whole analyzed frequency spectrum. Each trace represents one channel (i.e., one electrode).
One prominent peak is observed as expected, in the α range (8–12 Hz) (cf. eye-closed condition). Two additional peaks were seen within the low β (Lβ; 13–20 Hz,
light red color) and high β (Hβ; 20–30 Hz, light green color) sub-bands, both in patients (A) and in controls (B). No peak was observed in the delta (δ; 2–4 Hz, light
gray) frequency range. β peaks occurred, respectively, approximately 16 and 25 Hz in most participants, as illustrated by the two vertical black arrows in the two
insets showing the GPS computed over all frequencies derived from each main graph, respectively. GPS in the low β (Lβ), high β (Hβ), and δ frequency ranges for
chronic neuropathic pain patients and healthy controls. All data are shown as mean (SD). Non-normalized data (C): Patients displayed lower Lβ (13–20 Hz, red open
squares) GPS than controls [−4.7 (2.0) dB vs. 1.4 (2.9) dB] in a highly significant manner [t-test: t(20) = −3.226, p = 0.004]. Likewise, the difference between
patients’ Hβ (20–30 Hz, green open squares) GPS [−7.7 (1.9) dB] and controls [−5.4 (1.2) dB] was highly significant [t-test: t(20) = −3.271, p = 0.004]. Within the δ
(2–4 Hz, gray open squares) range, no significant GPS difference was observed between patients and controls [2.0 (1.7) and 3.4 (1.7) dB, respectively, t(20) = 1.919,
p = 0.069]. Normalized data (D): a significant decrease in Lβ (13–20 Hz, red open squares) GPS was noticed in patients compared with controls (GPS values are
positive due to computation of ratio between two negative numbers): 3.7 (1.4) dB vs. 5.7 (2.8) dB) [t-test: t(20) = −2.186, p = 0.041]. In the Hβ (20–30 Hz, green
open squares) range, the decrease was not anymore significant: 0.8 (1.4) vs. 1.6 (1.1) [t-test: t(20) = −1.610, p = 0.123].
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were anxious and had their pain intensity increasing with anxiety
level, and the influence of pain on their mood was measurable
in the anxiety domain. However, this study was not specifically
designed to measure this interaction. It should be noted that
no correlation was observed between the HADanx score and all
studied EEG markers.
DISCUSSION
In the present pilot study, we recorded β EEG oscillations
as an indicator of brain GABAergic activity (Christian et al.,
2015) in patients with lower limb CNP of peripheral origin
and matched controls, with the hypothesis that the β EEG
activity could be a biomarker of CNP. More specifically,
given the increased cortical excitation reported in chronic
pain situations (see later discussion), we expected the (inhibitory)
GABAergic signaling (and hence the β EEG activity) to
decrease in patients.
In our analyses, we considered the GPS as a quantitative
measurement of β EEG oscillatory activity. The most important
result of our study is that, in accordance with our assumptions,
the β GPS was significantly lower in patients than in healthy
controls both in the Lβ and in the Hβ frequency sub-bands
but not in the δ range (analyzed as a negative control).
Our results are in accordance with transcranial magnetic
stimulation, magnetic resonance spectroscopy, and EEG-based
measurements performed in chronic pain patients, which
found, respectively, decreased cortical inhibition (Barr et al.,
2013), cortical GABA concentrations (Baumgarten et al., 2016),
and lower γ oscillations (as GABAergic EEG marker) (Barr
et al., 2013) in pain controlling regions. However, some
studies reported rather increased β activity in neurogenic pain
(Sarnthein et al., 2006). Beyond the heterogeneity of studied
populations (i.e., mixed etiologies of neuropathic pain), several
methodological issues can be raised: acquired data were down-
sampled from 512 to 64 Hz, with a high risk of bias in
the final output considering the frequency range of interest;
data acquired with eyes closed were pooled together with
those recorded in eye-open conditions, which is reported to
dramatically modify both the topography and the magnitude
of different frequency components (Barry et al., 2007). In
addition, the wakefulness state was not segregated from
sleepiness or drowsiness in these studies, with the great risk of
slowing down the whole EEG recording pattern (Brown et al.,
2012). Finally, the β frequency domain was segmented with
different cutoffs. Other studies in patients with fibromyalgia,
a disease in which mechanisms generating chronic pain are
still elusive, reported at the same time increased (Lim et al.,
2016), unchanged (Fallon et al., 2018), or decreased (Mhalla
et al., 2010) cortical inhibition. Our study was conducted in a
homogenous population (patients suffered all from neuropathic
pain due to lesions in lower limb peripheral nerves), and data
analysis was standardized using validated methods [selection
of data recorded only in awaken state (Diaz et al., 2016)
and β frequency segmentation (von Rotz et al., 2017)] in
accordance with the two peaks observed in EEG data. Thus,
the present results can be considered as reliable under the
conditions in which the study was performed. The fact that
normalization did not vanish the significant decrease adds up
to the robustness of this finding. Furthermore, our data fit
better with the current understanding of the pathophysiological
mechanisms leading to chronic pain, i.e., a decreased brain
inhibition underpinned by a deficiency in GABAergic signaling
(Parker et al., 2016; Pelletier et al., 2017; Thibaut et al.,
2017), which seems to be more specifically associated with
neuropathic pain (Schwenkreis et al., 2010; Henderson et al.,
2013; Parker et al., 2016).
The Lβ (but not the Hβ or δ) GPS was highly correlated
with pain intensity when the latter was significant (Mantha
et al., 1993; Collins et al., 1997), reinforcing our working
hypothesis. However, the observed correlation disappeared after
normalization, as well as significance of Hβ GPS differences
between CNP patients and controls, which suggests that
there could be a bias related to other differences between
these two groups, such as in the GPS computed over the
full range of frequencies. Alternatively, considering that there
exists no standard among normalization methods that fits
all EEG data (Bogaarts et al., 2016), one could not exclude
the hypothesis that the discrepancy noticed between non-
normalized and normalized data is only the effect of a nonsuitable
normalization procedure. On the other hand, the small sample
size could itself explain this lack of significant results after
normalization. Overall, it seems that interpretation of differences
between non-normalized and normalized data is possibly not
unique and should be left open for further investigations
in larger studies and an adequate normalization procedure
clearly determined.
In conclusion, the association between Lβ GPS, supposedly
measuring brain GABAergic activity, and pain intensity suggests
that Lβ oscillations is a potential CNP biomarker, even if
the measured modality of pain is still to be more precisely
determined and these preliminary results confirmed in larger
investigation settings.
Given the major contribution of GABA to pain regulation,
we expected the reduction observed in the GABAergic markers
of pain (reflected by the GPSqmin) to be located within
the cerebral hemisphere contralateral to the pain side (Barr
et al., 2013). To our great surprise, GPSqmin localization was
irrespective of patients’ pain side in the Lβ as in the Hβ
frequency range. Furthermore, the distribution of both GPSqmin
and GPSqmax in Lβ and Hβ seemed to be similar in patients
and controls, with comparable lateralization trends in the
two groups. This finding would suggest a relationship with
nociception rather than with pathological pain. Interestingly,
most patients and controls (all right-handed) had their Lβ
GPSqmax located in the left and posterior hemisphere. A recent
study conducted in healthy right-handed individuals found a
positive and linear correlation between the β EEG oscillatory
activity and the endogenous concentration of GABA in the
somatosensory cortex only in the left hemisphere (Baumgarten
et al., 2016). Likewise, chronic pain diseased-patients displayed
left-lateralized structural changes in the sensory-motor cortex
areas (Baliki et al., 2012) and in the left posterior thalamus
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(Schmidt-Wilcke et al., 2007) (which has nociceptive projections
(Kramer et al., 2017a,b) to the somatosensory cortex (Viaene
et al., 2011; Castejon et al., 2016). Thus, it seems that the
GABAergic neurotransmission involved in nociception (more
specifically measured by Lβ GPS) is lateralized to the dominant
handedness hemisphere of both healthy and chronic pain
populations, in contradiction with previous data stating bilateral
or right-sided pain processing inputs (Coghill et al., 2001;
Favilla et al., 2014).
If we consider that Lβ GPS was strongly correlated to pain
intensity, we could further assume that Lβ might represent the
sensory modality of pain (supposedly measured by the VAS
(Boggero and Carlson, 2015). On the other hand, the correlation
between Hβ GPS and pain intensity (VASd) was only at the
edge of significance, whereas VASd was positively correlated
with HADanx. Interestingly, emerging data suggest that Hβ
GPS could possibly be related to anxiety and similar mood
disorders, pointing out rather an increase of β oscillations in
this context (Roohi-Azizi et al., 2017; Ribas et al., 2018). In
contrast, our data failed to show that the correlation between
Hβ GPS and HADanx. Since HB GPSqmax was mostly located
in the anterior quadrants, Hβ GPS could be related to the
affective component of pain (Boggero and Carlson, 2015), of
which controlling structures are located more anteriorly in the
brain (Kuner and Kuner, 2020), thereby making the evoked
link with the affective life. However, because the present study
was not designed to distinguish between the sensory and the
affective components of pain, further investigations are needed
to explore more precisely the hypotheses mentioned earlier.
Additionally, localization in the sensor space of EEG signals is
subject to discussion (Rutkove, 2007), whereas leg representation
in the sensory homunculus is close to the midline, making
it difficult to reliably determine the lateralization side. More
accurate analyses (e.g., source localization) are needed to get
more insight into this issue.
Overall, our data suggest a plausible relation between CNP and
the GABAergic EEG makers investigated and, more specifically,
the Lβ GPS, in accordance with our working hypothesis. The Hβ
GPS, less consistently associated with pain, could be related to
affective parameters such as anxiety or the affective component
of pain. However, we should be cautious in generalizing our
conclusions or extrapolating them to other settings given the low
number of participants in this study and the differences induced
by data normalization. In addition, it is difficult to further specify,
at this stage, what is exactly being measured through these EEG
markers, knowing that β oscillations have also been associated
with other brain functions or pathological situations (Mallet et al.,
2008; Mirzaei et al., 2017; Clarke et al., 2018; Mane et al., 2018).
On the other hand, one could argue that the found differences
and correlations are related in general to sensory symptoms of
the patients’ neuropathy and not specific to pain. However, the
patients’ neurological examination found only minor sensory
deficits unequally distributed among patients. If sensory deficits
had played a significant role in these findings, the consistency
of data would not be as remarkable as observed. Thus, we think




The present pilot study aimed at studying the β EEG oscillatory
activity as a GABAergic marker indexing chronic pain, having
in mind the need for a better and more objective evaluation
and mechanistic classification of pain to improve analgesic
treatment efficiency.
In line with our main hypothesis, we found that CNP
patients had lower EEG Lβ GPS than healthy controls and
that Lβ power was negatively correlated to pain intensity.
However, when data were normalized to the total GPS, the
correlation between Lβ GPS and pain intensity was not found
anymore. It also seemed that Lβ-related nociceptive GABAergic
neurotransmission could be lateralized in somatosensory brain
areas of the handedness-dominant hemisphere, in contradiction
with the current knowledge.
These preliminary results, although needing confirmation,
open the possibility for an objective evaluation of pain by means
of a short (24-min) EEG recording at rest. Furthermore, the
marker we studied seems to be solely related to GABAergic
signaling (and presumably to GABA cortical concentration). This
should therefore open a way to a mechanism-based classification
of pain and subsequently toward a more personalized GABA-
based analgesic therapy depending on the extent to which the
GABAergic signaling is involved.
In the future, it would be interesting to study the same markers
in other pain models, assessing the role played by GABA in their
underlying mechanisms.
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